Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cloratadd D vs Claritin D in Allergic Rhinitis
NCT01055756Phase 3Withdrawn
- Sponsor
- Azidus Laboratories Limited
- Start
- Jan 2010
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of loratadine + pseudoephedrine in allergic rhinitis (AR) (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoints: Clinical signs and symptoms score at 12 hours and Nasal flow at 12 hours. Planned start Jan 2010; status: withdrawn.
02
Drugs
loratadine + pseudoephedrine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01055756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01055756.